التفاصيل البيبلوغرافية
| العنوان: |
Fragments: where are we now? |
| المؤلفون: |
Osborne, James, Panova, Stanislava, Rapti, Magdalini, Tatsuya Urushima, Jhoti, Harren |
| المصدر: |
Biochemical Society Transactions; Feb2020, Vol. 48 Issue 1, p271-280, 10p |
| مصطلحات موضوعية: |
INDUSTRIAL chemistry |
| مستخلص: |
Fragment-based drug discovery (FBDD) has become a mainstream technology for the identification of chemical hit matter in drug discovery programs. To date, the food and drug administration has approved four drugs, and over forty compounds are in clinical studies that can trace their origins to a fragment-based screen. The challenges associated with implementing an FBDD approach are many and diverse, ranging from the library design to developing methods for identifying weak affinity compounds. In this article, we give an overview of current progress in fragment library design, fragment to lead optimisation and on the advancement in techniques used for screening. Finally, we will comment on the future opportunities and challenges in this field. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biochemical Society Transactions is the property of Portland Press Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
